LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)
Active, not recruiting · Phase 2 · NCT03946527
Conditions: Paraganglioma, Pheochromocytoma
At a glance
- Research payments reported, 2025
- $382,480
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 10
About the trial
- Sponsor
- Antonio Fojo (with Ipsen)
- Tested
- Lanreotide (drug)
- Dates
- Started 2019-06-17; completion 2027-03
- Results posted
- Not yet
The objectives of this study are: * To assess the efficacy of lanreotide given every 4 weeks in participants with advanced or metastatic paraganglioma/ pheochromocytoma. * To assess the toxicity and safety of lanreotide in participants with advanced or metastatic paraganglioma/ pheochromocytoma. * To document the effects of lanreotide on markers of biochemical activity in participants with advanced or metastatic paraganglioma/ pheochromocytoma. Primary endpoints: • Assess efficacy by estimating the tumor growth rate while a patient is enrolled on study and comparing the growth rates on lanreotide to the pre-enrolment growth rate. Secondary endpoints include measurement of: * Overall survi…
From ClinicalTrials.gov, last updated 2026-03-02. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ipsen Biopharmaceuticals, Inc reported $382,480 in research payments for this study in 2025 (1 payments).
Products named: Somatuline Depot
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- The Trustees of Columbia University $382,480
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.